HIV Clinicians Society Conference TB/HIV Treatment Cascade

Similar documents
SA TB Guidelines The interface with Advanced Clinical Care

Supplementary appendix

Assessing the programmatic management of drug-resistant TB

Soedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital

Xpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection. Results of Group Work

Xpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10

Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation

The New WHO guidelines on intensified TB case finding and Isoniazid preventive therapy and operational considerations

Kenya Perspectives. Post-2015 Development Agenda. Tuberculosis

Multidrug-Resistant TB

TOG The Way Forward

CULTURE OR PCR WHAT IS

Principle of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos

Ministry of Health. National Tuberculosis Control Program INTEGRATED TB HIV PROGRAM REPORT (JANUARY JUNE 2015)

How best to structure a laboratory network with new technologies

Costing of the Sierra Leone National Strategic Plan for TB

Heather Alexander, PhD

Definitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013

Diagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm

Scaling up collaborative TB/HIV activities: achievements, challenges, and opportunities in Viet Nam

Health Care Worker Training on Roll Out New TB Diagnostic Test. Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien)

The innovation gaps and challenges for MDR-TB. Blessina Kumar TB/ HIV Activist Community Representative & Vice Chair STBP Coordinating Board

MODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)

Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB

Cost-effectiveness of ART and the Three I s for HIV/TB to prevent tuberculosis

Virtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT

11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

WR s Speech on inaugural ceremony of Community based Programmatic Management of Drug resistance TB (CPMDT).

TB/HIV Monitoring & Advocacy Project Interview Tool

The Lancet Infectious Diseases

SOUTH AFRICA S TB BURDEN - OVERVIEW

Response to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria.

Infection Control in Tanzania

IPT IMPLEMENTATION- SWAZILAND EXPERIENCE

NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis

Intensified TB Case Finding using a TB screening tool integrated into an HIV clinical record: Experiences from the Eastern Cape Province

TB infection control: overview and importance

Let s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite

TB: A Supplement to GP CLINICS

WHERE DO WE GO FROM HERE?

Dr Richard Christopher,(Pediatrician) Ministry of Health and Social Welfare NTLP- TANZANIA Tanzania. Childhood TB Roadmap Paris 0ctober 29

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

Progress Report March 2016

UGANDA NATIONAL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges

Xpert MTB/RIF test Rollout and Implementation Plan

The Health Economics and Epidemiology Research Office (HE 2 RO): An overview of research methods and results

Report on WHO Policy Statements

Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor

INTENSIFIED TB CASE FINDING

Challenges in Capacity in SA for diagnosing DR-TB

Phase III Clinical Trial Results at the 48 th Union World Conference on Lung Health: Implications for the Field 1

SAME-DAY-DIAGNOSIS OF TUBERCULOSIS BY MICROSCOPY - POLICY STATEMENT -

Controlling TB in the era of HIV

Current status of implementation and monitoring and evaluation of collaborative TB/HIV activities. Avinash Kanchar

Revised National Tuberculosis Control Programme

COMMUNITY-BASED TBHIV CASE-FINDING KENYAN EXPERIENCE

Ken Jost, BA, has the following disclosures to make:

Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it

Session-1: Template for country presentation (EXISTING Indicators)

Application of the Onion model to assess the extent of missing tuberculosis cases by the National Programmes

: uptake and impact of Xpert MTB/RIF

Tuberculosis Screening and IPT: Experience from India

Overview of the Presentation

Same-day diagnosis of tuberculosis by microscopy. Policy statement

Xpert MTB/RIF assay validation experience --- impact and plan in China

TB FIT Modelling. 24th Annual PhilCAT Convention. Ivor Langley and Ewan Tomeny Liverpool School of Tropical Medicine AUGUST 2017

The first National TB Prevalence Survey Rwanda 2012

SURVEY FINDINGS April 28, 2017

Online Annexes (2-4)

Eswatini NTCP and Baylor Global TB Pilot Project on DR-TB Contact Management. WHO Child and Adolescent Working Group October 2018 Dr Debrah Vambe

Treating HIV and TB: New evidence, Challenges & Prospects

Intensive Case Finding of TB in Children Using the MCH approach

What is new in WHO-guidelines relevant for childhood TB?

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

Online Annexes (5-8)

FAST pilot to scale-up: Lessons learnt from Nigeria

ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM

ADDRESSING MDR TB IN THE CONTEXT OF HIV: Lessons from Lesotho. Dr Hind Satti PIH Lesotho Director MDR-TB program

World Journal of Pharmaceutical and Life Sciences WJPLS

International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007

Online Annexes (5-8)

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building

The emerging threat of multidrug resistant TB: Global and local challenges and solutions

Treatment of Active Tuberculosis

DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?

The need for new TB diagnostics in children and the way forward

Update on Management of

TB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai

MDR TB. Jaime C. Montoya MD, MSc

Finding the missing TB cases

Modeling the diagnosis of HIVassociated

New Standards for an Old Disease:

Tuberculosis in children: gaps and opportunities

Managing the Revised National Tuberculosis Control Programme in Your Area. A Training Course. Modules 1 4

Transcription:

HIV Clinicians Society Conference-2012 TB/HIV Treatment Cascade Dr Judith Mwansa-Kambafwile Wits Reproductive Health & HIV Institute University of Witwatersrand

TB/HIV Treatment Cascade Overview TB stats (global and in South Africa) TB/HIV treatment cascade An overview the patient flow at a PHC Targets for the South African NDoH Impact of Xpert MTB/RIF

Tuberculosis MDG goal to halt and reverse TB globally has been achieved 2.2% drop in new TB cases between 2010 and 2011 41% decrease in mortality since 1990 (target was 50% by 2015) However, global burden still high A national epidemic in S.A. Incidence now at 993/100000 population TB/HIV co-infection rates Globally = 13% South Africa = 65% TB is leading cause of mortality among HIV positive individuals Reference: WHO Global TB Report 2012

Estimated TB incidence rates, 2011 Reference: WHO Global TB Report 2012

Estimated HIV prevalence in new TB cases, 2011 Reference: WHO Global TB Report 2012

TB/HIV treatment cascade Delivery of services to persons co-infected with TB and HIV at the various steps in the continuum of care Diagnosis Retention in care Outcomes Not all TB can be integrated into HIV programs and vice versa From R.S.A stats, at least 35% of TB patients do not have HIV (WHO Global TB Report-2012) But all TB patients must be tested for HIV and all HIV positive people must be screened for TB Helps to understand patient flow regarding these 2 services Helps to identify barriers and gaps to service delivery, and therefore strategize plans to overcome these obstacles

What happens to a person visiting a PHC because they feel sick (for example having TB symptoms)? A process map

Patient comes into PHC Pick up their folder from reception Wait to be seen (meantime health education given by a counselor) Clinical assessment Given 2 sputum bottles (1 to produce sputum then and the other to bring following morning If no Sxs, HIV+, consider IPT AFB- If Sxs, HIV+, follow algorithm for smear negative TB Counseled on the results AFB+ Counseled and offered HIV test if status unknown Patient comes in after 2-3 days to receive results Start TB Rx Sputum for monitoring at 2 or 3 months Patient brings 2 nd sputum next morning and asked to come back after 2-3 days for results Complete TB Rx (smears to be collected) HIV- HIV+ (CTX given) Counsel and ask to repeat test after 6 weeks/start TB Rx ART work up/start TB Rx

No previous TB or less than 4 weeks of TB treatment Send 2 sputum specimens for smear microscopy: 1 st spot specimen taken at the health facility under supervision 2 nd early morning specimen Smear Negative TB HIV- negative or HIV status unknown HIV positive AFB+ AFB+ AFB+ AFB- AFB+ AFB- AFB- AFB- AFB+ AFB+ AFB- AFB- Provide full course of treatment Provide antibiotics. Provide full course of treatment Send 3 rd specimen for smear and culture. If no improvement: Send 3 rd specimen for sputum smear and culture Do chest x-ray. Do chest x-ray.. AFB+ AFB- and AFB- AFB- AFB+ AFB- and TB on chest x-ray and Medical officer decision to treat on clinical grounds No TB on chest x-ray TB on chest x-ray and Medical officer decision to treat on clinical grounds No TB on chest x-ray Aim to provide full course of treatment. Review clinical picture and progress when culture result available for smear negative cases. Consider other diagnosis. Review TB culture result. Aim to provide full course of treatment. Review clinical picture and progress when culture and drug sensitivity available for smear negative cases. Consider other diagnosis. Review TB culture result.

TB Diagnosis using Xpert MTB/RIF TB SUSPECTS TB and DR-TB contacts, non-contact symptomatic individuals, re-treatment after relapse, failure and default Collect one sputum specimen at the health facility under supervision GXP positive Rifampicin susceptible GXP positive Rifampicin resistant GXP positive Rifampicin unsuccessful GXP negative GXP unsuccessful Start on Regimen 1 Send one specimen for microscopy Treat as MDR-TB Refer to MDR-TB Unit Start on Regimen 1 Collect one specimen for microscopy Culture & DST / LPA HIV positive HIV negative Collect one sputum specimen for a repeat GXP Collect one specimen for culture and LPA or culture and DST (for R and H) Treat with antibiotics and review after 5 days Do chest x-ray Treat with antibiotics Follow up with microscopy Collect one specimen for microscopy, culture and DST for Rifampicin, Isoniazid, fluoroquinolone and Aminoglycoside Poor response to antibiotics Clinically TB TB on chest x-ray LPA/ DST results Resistant to R and H/ R only Good response No further follow up Advise to return when symptoms recur Poor response Consider other diagnosis Refer for further investigation Follow up with microscopy and culture Start on Regimen 1 Review culture results Treat as MDR-TB Refer to MDR-TB Unit

We have seen the steps. Complicated?? Maybe So what do we want??.. To achieve our targets..

R.S.A Targets Test all TB patients for HIV (100%) Initiate ART in all that are eligible All TB/HIV co-infected eligible Check for smear conversion before continuation phase (>80%) not always evaluated Ensure minimal defaulter rate (<5%) Ensure Rx completion and check smear before discharging (>80%) Always rule out smear negative TB before labeling a patient as not having TB

Where are we (R.S.A) at? TB incidence and notifications Reference: WHO Global TB Report 2012

Where are we (R.S.A) at? TB treatment success rate Reference: WHO Global TB Report 2012

Where are we (R.S.A) at? TB/HIV Reference: WHO Global TB Report 2012

What has been the impact of having XPERT MTB/RIF?

TB Diagnosis using Xpert MTB/RIF TB SUSPECTS TB and DR-TB contacts, non-contact symptomatic individuals, re-treatment after relapse, failure and default Collect one sputum specimen at the health facility under supervision GXP positive Rifampicin susceptible GXP positive Rifampicin resistant GXP positive Rifampicin unsuccessful GXP negative GXP unsuccessful Start on Regimen 1 Send one specimen for microscopy Treat as MDR-TB Refer to MDR-TB Unit Start on Regimen 1 Collect one specimen for microscopy Culture & DST / LPA HIV positive HIV negative Collect one sputum specimen for a repeat GXP Collect one specimen for culture and LPA or culture and DST (for R and H) Treat with antibiotics and review after 5 days Do chest x-ray Treat with antibiotics Follow up with microscopy Collect one specimen for microscopy, culture and DST for Rifampicin, Isoniazid, fluoroquinolone and Aminoglycoside Poor response to antibiotics Clinically TB TB on chest x-ray LPA/ DST results Resistant to R and H/ R only Good response No further follow up Advise to return when symptoms recur Poor response Consider other diagnosis Refer for further investigation Follow up with microscopy and culture Start on Regimen 1 Review culture results Treat as MDR-TB Refer to MDR-TB Unit

Early diagnosis Early treatment initial defaulter rate Less transmission DR-TB detected early Ultimately leading to. Low incidence Low prevalence TB free communities

Things to consider POC XPERT MTB/RIF? Same visit Rx initiation for those found to be positive Sustainability Logistical issues e.g. power and water supply Cost effectiveness Validity of results and machine maintenance POC use of Xpertis feasible at the PHC level but must be accompanied by financial, operational and logistical support (Clouse et al, Sept 2012)